Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.20B
EPS-6.8600
P/E Ratio-1.65
Earnings Date08/10/2026

bhvn

Cash and Cash Equivalents

Last Annual Value

229.96M

3-Year CAGR

4%

5-Year CAGR

23%

10-Year CAGR

6%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Cash and Cash Equivalents

BHVN · NYSE
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
229.96M
-2.5%24.8%N/A 
155.46M
-11.8%4.7%-5.5%
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
653.48M
87.8%67.7%N/A
354.73M
98.0%34.8%N/A
58.45M
14.9%N/AN/A
110.64M
24.8%N/AN/A
111.04M
18.1%10.5%13.2%
28.87M
-6.0%-5.9%-3.8%
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $11.35